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Introduction. Adrenocortical carcinoma is a rare tumor with an annual incidence of 1–2 cases/million habitants and it is more
common in adult women. 80% are functioning and they are diagnosed in early stages. The best treatment is radical surgery
with SLE of 30%. Adjuvant radiotherapy can improve local disease control.Objectives. To show the simulation and planning
methodology of a rare neoplasiaMaterial and methods. 44 year old women diagnosed of adrenocortical carcinoma not functioning
of 11 cm, located in left adrenal gland treated with adrenalectomy and radiotherapy. To deﬁne more accurately the volume of
treatment, we decided to fuse simulation images and diagnostics TAC. The treatment was done in two phases, given 50.4Gy
in 1.8Gy fractions with high energy photons from a linear accelerator and multiple coplanar ﬁelds and isocentric shaped with
multileaf. The patient presented only as gastrointestinal acute enteritis grade 1. At 6 months of diagnosis, is asymptomatic and
without locoregional relapse data.Conclusions. We don’t found randomized studies about the adjuvant radiotherapy treatment in
this case so the fusion of images allow to delineate with great precision the volumes before surgery to get good coverage while
minimizing the dose to organs at risk, especially in large tumors that produce large anatomical distortion after surgery, to treat
this patient with the radiotherapy administered.
http://dx.doi.org/10.1016/j.rpor.2013.03.187
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Primary pancreatic lymphoma (PPL) is rare, comprising less than 0.5% of pancreatic tumours. Should distinguish between PPL and
other secondarymass of thepancreas. The clinical anddiagnostic criteria of PPL include:masspredominantlywithin thepancreas
with grossly involved lymph nodes conﬁned to the peripancreatic region, no palpable superﬁcial lymphadenopathy, no hepatic
or splenic involvement, no mediastinal nodal enlargement on chest radiograph, and normal white cell count. The symptoms
are non-speciﬁc, typically including abdominal pain, weight loss, nausea and vomiting. PPL can be difﬁcult to differentiate
from pancreatic adenocarcinoma without deﬁnitive pathological and correct diagnosis is crucial given that PPL has differing
management and usually a much better prognosis. Optimal treatment of PPL remains controversial. Radiation therapy and
chemoimmunotherapy may be are effective. We report a case of primary pancreatic lymphoma presenting as a pancreatic
mass. CASE: a 58 year old man presented epigastric and back pain. 3 kg of weight loss over 2 months. Ultrasound and CT
revealed a 12 cm pancreatic head mass involving duodenum; with lymphadenopathy conﬁned to the peripancreatic region,
histopathology from PAAF of the pancreatic mass was consistent for non-Hodgkin’s lymphoma with CD20 and BCL2. Histological
Grade I.Mediastinal lymphuptake in PET scanwith EBUSnegative. Resectionwas not performed. Treatment consisted of involved
ﬁeld radiotherapy (39.6Gy in 22 fractions), with previously chemotherapy regimen CHOP for 8 cycles and sequential Rituximab for
4 cycles. Good tolerance in full treatment, without toxicity. Restaging conﬁrmed sustained response, and the patient remains free
fromprogression at 15months following diagnosis.Conclusion. PPL is a rare but potentially curable pancreatic tumour, pathological
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diagnosis is mandatory for all pancreatic mass, as its treatment and prognosis differs from adenocarcinoma. Radiotherapy may
be effective.
http://dx.doi.org/10.1016/j.rpor.2013.03.188
Adjuvant treatment in locally advanced gastric cancer: A monoinstitutional experience
I. Formoso García1, A. Carballo Castro1, P. Calvo Crespo1, B. Taboada Valladares1, C. Ponte García1,
P. Peleteiro Higuero1, A. Varela Pazos1, J. Castro Gómez2, U. Anido Herranz3, E. Ambroa Rey4, A. Álvarez Castro5,
P. Parada González6, L. Lesquereux Martínez6, A. Gomez Caaman˜o1
1 Complejo Hospitalario Universitario de Santiago, Oncología Radioterápica, Spain
2 Complejo Hospitalario de Ourense, Oncología Radioterápica, Spain
3 Complejo Hospitalario Universitario de Santiago, Oncología Médica, Spain
4 Complejo Hospitalario Universitario de Santiago, Radiofísica Hospitalaria, Spain
5 Complejo Hospitalario Universitario de Santiago, Digestivo, Spain
6 Complejo Hospitalario Universitario de Santiago, Cirugía General y Digestiva, Spain
Introduction. In localised gastric cancer, surgery remains the cornerstone of treatment. Nevertheless the dismal outcome has
led to a large debate regarding the role of adjuvant treatment in addition to surgery. The aim of the study was to evaluate the
outcome of adjuvant RCT in terms of local control and survival for locally advanced gastric cancer in our institution.
Materials. Between April-2001 and March-2012, 71 patients with locally advanced gastric cancer were treated with adjuvant
chemo-radiotherapy regimen. Median age was 66 (38–81) years. Location tumours were: cardias 9.9%, body-fundus 36.6% and
antro-pylorus 53.5%. 91.5% of patients received adjuvant bolus ﬂuoropyrimidine-based chemotherapy previous to concomitant
treatment; 7% receivedotherQTand1.4%none. 3DCRT radiotherapywasused, delivereddosewas 45–50.4Gy (1.8Gy/day) in 93%of
cases; 7%of cases didnot received treatment. Concomitant chemotherapy regimesusedwere 66.2% continuousﬂuoropyrimidine-
based chemotherapy, 29.6% bolus ﬂuoropyrimidine-based chemotherapy and 1.4% PFL; 2.8% of cases none. Pathologic stage was
11.3% IB, 23.9% IIA; 25.4% IIB, 18.3% IIIA, 21.1% IIIB. Surgery was performed in 100% of patients (total gastrectomy was 23.9%;
partial gastrectomy was 73.2% and 2.8% others).
Results. Median follow-up was 37, 5 months (7-98). 5-year actuarial overall survival (OS) was 60%; 5-year disease-free survival
(DFS) was 57%, and 5-year local progression free survival (LPFS) was 59%. Medium DFS was 61.53 months (95% CI: 51.7–71.35) and
medium OS was 66.07 months (95% CI: 56.73-75.42). Grade 3-4 toxicity: 7% diarrhea; 7% mucositis, 9.8% anemia; 1.4% neutropenia;
2.8% nauseas; 2.8% vomits; 2.8% asthenia, 2.8% anorexia and 1.4% hand-foot syndrome.
Conclusions. Prognosis of gastric cancer remains dismal, high relapse rates indicate the need for adjuvant therapy as an integral
part of treatment. Our results conﬁrm that adjuvant RCT is feasible approach for gastric cancer, offering good outcomes in-ﬁeld
tumour control, low toxicity proﬁle and overall survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.189
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Introduction. For themajority of patientswith stages II and III rectal cancer is recommended combined-modality therapy consisting
of radiation therapy, chemotherapy and surgery. Preoperative radiotherapy combined with oral capecitabine is considered as the
standard treatment in this situation.
Objective. The purpose of this study is to evaluate the results obtained with preoperative chemoradiotherapy using capecitabine
in terms of downstaging, distal and local recurrence and survival.
Method. Between January 2005 and December 2011, 117 patients with histological diagnosis of rectal adenocarcinoma stages II-III
were treated with preoperative 3D radiotherapy (50.4Gy) combined with capecitabine 825mg/m2/12h daily during the complete
course of radiation. Surgery was performed 6–8 weeks after the end of combined treatment. Staging workup in all patients
consisted in colonoscopy, endorectal ultrasound, pelvic MRI and PET-CT. Most of the patients were men and the mean age of
the series was 62 years. Clinical Staging TN was as follows: T2 (6%), T3 (71%), T4 (23%), N0 (38%), N1 (42%), N2 (20%). Surgical
procedures using total mesorectal excision were: low anterior resection (60%) and abdominoperineal resection (38%). The mean
follow-up of the series was four years.
Result. The rate of pathologic complete response obtained in this series was 22%. Tumor downstaging was observed in 66%, node
downstaging in 50.5% and TN downstaging in 34%. With a mean follow-up of more than four years the rate of local recurrence
observed was 5% and distance recurrence of 22%. The mean survival at four years was 88% and the disease free survival at four
years was 70%.
